Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 12;28(16):3433–3442. doi: 10.1158/1078-0432.CCR-22-0305

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 4. Outcomes by PIK3CA mutation status in ctDNA at day 1 or end of treatment. PFS by treatment (A), OS regardless of treatment (B), and OS by treatment (C). ctDNA = circulating tumor DNA; FUL = fulvestrant; HR = hazard ratio; mut = mutation; OS = overall survival; PAL = palbociclib; PBO = placebo; PFS = progression-free survival; PIK3CA = phosphatidylinositol 3-kinase catalytic alpha polypeptide; WT = wild type. — Outcomes by PIK3CA mutation status in ctDNA at day 1 or end of treatment. PFS by treatment (A), OS regardless of treatment (B), and OS by treatment (C). ctDNA, circulating tumor DNA; FUL, fulvestrant; HR, hazard ratio; mut, mutation; OS, overall survival; PAL, palbociclib; PBO, placebo; PFS, progression-free survival; PIK3CA, phosphatidylinositol 3-kinase catalytic alpha polypeptide; WT, wild type.